ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ANI Pharmaceuticals, Inc. (ANIP) Healthcare & Pipeline Overview

ANI Pharmaceuticals, Inc. specializes in the development and manufacturing of a wide range of branded and generic pharmaceuticals, including controlled substances and oncology products, positioning itself as a key player in the specialty and generic drug market in North America.

What Is the Investment Thesis for ANIP?

With a market capitalization of $1.62B and a P/E ratio of 14.80, the company demonstrates solid profitability, evidenced by a profit margin of 9.7% and a gross margin of 52.6%. Key growth catalysts include the expansion of its product portfolio through new drug approvals and the increasing demand for specialty pharmaceuticals, which is projected to grow significantly over the next five years. Additionally, ANI's contract manufacturing services provide a stable revenue stream, further enhancing its financial stability. However, potential risks include regulatory challenges and market competition, which could impact future growth. Overall, ANI Pharmaceuticals stands to benefit from its strategic positioning and operational efficiencies in the biopharmaceutical landscape.

Based on FMP financials and quantitative analysis

ANIP Key Highlights

Market capitalization of $1.62B reflects strong market presence and investor confidence.

• P/E ratio of 14.80 indicates a reasonable valuation relative to industry peers.
• Profit margin of 9.7% showcases effective cost management and operational efficiency.
• Gross margin of 52.6% exceeds industry averages, highlighting strong product pricing power.
• Beta of 0.46 suggests lower volatility compared to the broader market, indicating stability.

Who Are ANIP's Competitors?

ANIP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ANIP's Key Strengths?

Diverse product portfolio across various therapeutic areas.

• Strong gross margins indicating effective cost management.
• Established reputation for quality and compliance in manufacturing.
• Robust distribution network enhancing market reach.

What Are ANIP's Weaknesses?

Dependence on a limited number of key products for revenue.

• Exposure to regulatory changes that may impact operations.
• Limited international presence compared to larger competitors.
• No dividend payments may deter income-focused investors.

What Could Drive ANIP Stock Higher?

ANIP catalyst: Expansion of product pipeline with several new drug approvals anticipated within the next 12-18 months.

• Continuous investment in research and development to enhance product offerings and address unmet medical needs.
• Strengthening of contract manufacturing services to capitalize on growing demand in the pharmaceutical sector.
• Exploration of new geographic markets to increase international sales and diversify revenue streams.
• Strategic partnerships aimed at enhancing product development and distribution capabilities.

What Are the Key Risks for ANIP?

Insider selling — insiders were net sellers of roughly $8.1M recently.

• Regulatory challenges that may delay product approvals or impact market entry.
• Intense competition from larger pharmaceutical companies and generic manufacturers.
• Fluctuations in raw material costs affecting production margins.
• Market volatility that could impact pricing strategies and demand for products.

What Are the Growth Opportunities for ANIP?

• Expansion in Oncology: ANI Pharmaceuticals is poised to expand its oncology product line, which is projected to grow significantly as cancer prevalence increases. ANI's expertise in this area positions it to capture market share through innovative product offerings and strategic partnerships.
• Contract Manufacturing Services: The demand for contract manufacturing in the pharmaceutical sector is on the rise, with the market expected to grow to $150 billion by 2026. ANI's established capabilities in contract development and manufacturing allow it to leverage this trend, providing tailored solutions for other pharmaceutical companies and enhancing its revenue diversification.
• Geographic Expansion: ANI Pharmaceuticals is exploring opportunities to enter new international markets, particularly in Europe and Asia, where the demand for specialty pharmaceuticals is increasing. This expansion could significantly enhance its market presence and revenue potential, especially in regions with growing healthcare expenditures.
• Product Pipeline Development: ANI's ongoing investment in research and development is expected to yield new product approvals in the coming years. With a focus on high-demand therapeutic areas, the company aims to introduce several new products, which could drive revenue growth and enhance its competitive positioning in the market.
• Strategic Partnerships: Collaborating with other pharmaceutical companies for co-development and distribution can provide ANI Pharmaceuticals with access to new technologies and markets. These partnerships can accelerate product development timelines and enhance market reach, contributing to sustained growth.

What Are ANIP's Competitive Advantages?

• Strong focus on niche markets reduces direct competition and enhances pricing power.
• Established reputation for quality and compliance fosters customer trust and loyalty.
• Diverse product portfolio mitigates risks associated with reliance on a single product line.
• Robust distribution network ensures wide accessibility of products across various channels.
• Contract manufacturing capabilities provide additional revenue streams and market flexibility.

What Does ANIP Do?

ANI Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Baudette, Minnesota. The company has established itself as a prominent biopharmaceutical entity focused on the development, manufacturing, and marketing of both branded and generic prescription pharmaceuticals across the United States and Canada. ANI Pharmaceuticals primarily targets niche markets, including controlled substances, oncology products, hormones and steroids, and injectables, which allows it to differentiate itself in a competitive landscape. The company manufactures a variety of dosage forms, including oral solid doses, semi-solids, liquids, and topicals, and also engages in contract development and manufacturing services for other pharmaceutical firms. This dual focus on proprietary products and contract services enhances its revenue streams and market reach. ANI Pharmaceuticals leverages a robust distribution network that includes retail pharmacy chains, wholesalers, distributors, mail order pharmacies, and group purchasing organizations, ensuring its products are widely accessible. The company's commitment to quality and compliance with regulatory standards has positioned it favorably within the biopharmaceutical sector, allowing it to maintain a competitive edge in an evolving market.

What Products and Services Does ANIP Offer?

• Develops and manufactures branded and generic prescription pharmaceuticals.
• Focuses on controlled substances, oncology products, hormones, and injectables.
• Offers contract development and manufacturing services to other pharmaceutical companies.
• Markets products through various channels including retail pharmacies and wholesalers.
• Produces a range of dosage forms including oral solids, semi-solids, liquids, and topicals.
• Maintains compliance with regulatory standards to ensure product quality and safety.

How Does ANIP Make Money?

• Generates revenue through the sale of branded and generic pharmaceuticals.
• Offers contract manufacturing services, providing tailored solutions for other pharmaceutical companies.
• Utilizes a diverse distribution network to reach various customer segments.
• Focuses on niche markets to differentiate product offerings and reduce competition.
• Invests in research and development to expand product pipeline and enhance market presence.

What Industry Does ANIP Operate In?

The drug manufacturing industry, particularly in the specialty and generic segments, is experiencing robust growth driven by increasing healthcare demands and an aging population. The global specialty pharmaceuticals market is projected to reach approximately $500 billion by 2027, with a CAGR of over 10%. ANI Pharmaceuticals operates within this dynamic landscape, focusing on high-demand therapeutic areas such as oncology and controlled substances. The competitive landscape includes established players and emerging biotech firms, necessitating continual innovation and regulatory compliance to maintain market share. ANI's strategic focus on niche products positions it well to capitalize on industry trends and emerging opportunities.

Who Are ANIP's Key Customers?

• Retail pharmacy chains that distribute prescription medications to consumers.
• Wholesalers and distributors that supply products to healthcare providers and pharmacies.
• Mail order pharmacies that cater to patients requiring regular medication deliveries.
• Group purchasing organizations that negotiate pricing on behalf of healthcare providers.
• Healthcare providers that prescribe specialty pharmaceuticals to patients.

Company Profile

ANI Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Baudette, United States.

Return on equity for ANI Pharmaceuticals, Inc. stands at 17.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.3%, showing how much profit it generates from its asset base. ANIP trades at a trailing price-to-earnings ratio of 14.80, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 9.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.6%, the inverse of the P/E and a quick read on earnings relative to price.

ANIP Valuation & Market Position

With a $1.62B market cap, ANI Pharmaceuticals, Inc. sits in the small-cap segment of the market. Analyst price targets span from $90.00 to $119.00, with a consensus of $104.33. At the current price of $71.46, that implies approximately 46% upside potential. Relative to its peer group, ANIP's quantitative score of 86/100 is above the peer average of 72/100.

Quarterly Financial Performance: ANI Pharmaceuticals, Inc.

Revenue for ANI Pharmaceuticals, Inc. came in at $266.0M during Q2 FY2026, a 12.0% improvement versus the preceding quarter. The company recorded net income of $24.7M, with diluted EPS of $1.13. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ANIP averaged $1.23 in diluted EPS.

ANI Pharmaceuticals, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.58 places it in the grey zone, a middle ground that warrants monitoring.

ANI Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 24.5% above estimates on average.

Over the past six months, ANI Pharmaceuticals, Inc. insiders filed 29 SEC Form 4 transactions — 21 sales and 8 purchases. On net that is roughly 74K shares disposed (about $8.1M), a signal worth weighing alongside the fundamentals.

ANIP Financials

ANIP Latest News

ANIP Analyst Consensus

ANIP MoonshotScore

Common Questions About ANIP (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources